Industry P pharmaphorum
Your DTP programme has five vendors and no spine
Your DTP programme has five vendors and no spine Nicole.Raleigh Mon, 19/10/2026 - 11:00
Industry headlines from across biotech and life sciences, gathered from the industry press and linked straight to the publisher. Every story links straight to its publisher.
Industry P pharmaphorum
Your DTP programme has five vendors and no spine Nicole.Raleigh Mon, 19/10/2026 - 11:00
Industry
Clinical Trials Arena
Lilly said it will supply data to the FDA to support the label expansion of Omvoh in paediatric UC. The post Lilly’s Omvoh leads to 50% clinical remission rate in paediatric UC appeared first on Clinical Trials Arena.
Industry P pharmaphorum
UK Biobank partners industry on 'most detailed' immune map Phil.Taylor Mon, 19/10/2026 - 10:34
Industry P Pharmafile
Beckman Coulter Diagnostics has appointed Catherine Jennings as its new President. In this role, Jennings will lead the company’s strategic, operational and organisational priorities, applying a culture of continuous improvement to accelerate innovation, strengthen global i…
Industry P Pharmaceutical Executive
Incubate’s John Stanford on why MFN deals are voluntary in name only — and why the leverage looks a lot like the IRA’s 95% excise tax.
Industry
BioPharma Dive
Saudi Arabia’s biotech strategy now has named partners, sites and capital behind it.
Industry P pharmaphorum
Data reveal is promising for GSK's lung cancer drug ris-rez Phil.Taylor Mon, 19/10/2026 - 08:52
Industry P pharmaphorum
From reactive to predictive: How data is redefining pharma logistics Nicole.Raleigh Mon, 19/10/2026 - 08:30
Industry
STAT Biotech
Isomorphic Labs wants to turn its technology into an engine for new medicines. The question now is whether — and how — it can deliver on that promise.
Industry
European Biotechnology
Each month, the European Medicines Agency’s human medicines committee (CHMP) weighs in on which drugs should reach European patients — and which should not. Here are eight decisions from its October meeting worth knowing. The post CHMP October decisions: AstraZeneca pulls prostat…
Industry
Pharmaceutical Technology
Estuary Biotherapeutics has launched after securing $103m in total committed financing for developing targeted gene therapies to treat kidney diseases.
Industry B BioTechniques
Original story from Hubrecht Institute (Utrecht, Netherlands). The intestines use the rhythm of a signal to decide which cells to make, improving our understanding of healthy tissue maintenance and disease disruption. A study conducted at the Hubrecht Institute (Utrec…
Industry S Science News
A tiny fossil tail offers the first “irrefutable” proof of a dropped tail
Industry S Science News
A 13-year study shows how sensitive deep-sea animals are to disturbance, scientists say
Industry S Science News
Industry
Nature Biotechnology
Industry N Nature Medicine
Industry N Nature Medicine
Industry
Inside Precision Medicine
Antibody patterns can signal whether a person will develop inflammatory bowel disease (IBD) and predict the severity of certain forms of the condition up to 10 years before diagnosis. The post Antibody Signatures Could Reveal IBD Risk 10 Years Before Diagnosis appeared first on I…
Industry
GEN
Two weeks after its stock lost more than half its value following a setback in a seven-year legal wrangle, Liquidia shares finally began bouncing back thanks to a settlement with United Therapeutics that drew mixed conclusions from four analysts about which company won out long-t…
Industry
Inside Precision Medicine
A study of more than two million surgical patients found that GLP-1 medications were associated with 11% lower odds of major cardiovascular complications and 8% lower odds of postoperative infections. The post GLP-1 Drugs Linked to Fewer Heart Complications and Infections After S…
Industry
MedCity News
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But Vertex Pharmaceuticals could also compete with a drug candidate from a recent acquisition. The post Startup…
Industry
MedCity News
This is not a discovery problem. It is a market entry and access problem, and it is far more tractable than the pipeline crisis we spend most of our attention on. The post The Antibiotics Exist —The System Cannot Deliver Them appeared first on MedCity News.
Industry A Applied Clinical Trials
Paradigm’s Kurt Mussina discusses why scale should drive operational efficiency, not consolidation into single-site studies.
Industry A Applied Clinical Trials
Paradigm’s Kurt Mussina touches on why he rejects the “site management organization” model in favor of one unified business.
Industry A Applied Clinical Trials
ProofPilot’s Lauren Briggs touches on why site tech adoption hinges on the first 90 days after rollout, and why tools succeed only when they remove work from a site’s plate rather than adding another login to juggle.
Industry A Applied Clinical Trials
Sequoia’s Dan White and Dr. Tom Kreamer touch on why sponsors and CROs should treat a site network as one centralized partnerto speed startup timelines and strengthen execution.
Industry A Applied Clinical Trials
Sequoia Clinical Research’s CEO Dan White and CMO, Dr. Tom Kreamer explain what it takes to merge three site organizations into one network.
Industry
TechCrunch Biotech and Health
Mark Wahlberg, who once sank money into a gym chain that got kicked off the NYSE, is now building his own, and he promises you’ll get a cold plunge, a blood panel and a protein muffin without needing a trust fund.
Industry
BioCentury
BIOCENTURY | PRODUCT DEVELOPMENTTHE FUTURE OF RNAI WITH ARROWHEAD’S CHRIS ANZALONE ON THE BIOCENTURY SHOWCEO’s view on solving extra-hepatic siRNA delivery and Arrowhead’s future growth opportunities
Industry
BioCentury
BIOCENTURY | FINANCEAFTERMARKET GAINS FOR CITY, IAMBIC: PUBLIC EQUITY REPORTPlus: Aspen, Bambusa enter NASDAQ queue; financings for Akeso, Verastem, First Tracks and more
Industry S SecureBio
Clarifying our current engagement with Anthropic, and how we approach independence and publication rights in our work with AI developers.
Industry
C&EN Pharmaceuticals
The start-up is targeting the most common form of inherited kidney disease
Industry
GEN
This eBook brings insight on integrated end-to-end solutions for precision engineered therapeutics. The post ADC Developmentfrom Concept to Clinic appeared first on GEN - Genetic Engineering and Biotechnology News.
Industry
MedTech Dive
Edwards is asking customers to return some of the delivery systems used with its Sapien M3 devices after receiving three reports of balloons bursting when inflated during the procedure.
Industry
GEN
This proceedings eBook, developed in partnership with GEN and Cincinnati Children’s Hospital Applied Gene and Cell Therapy Center, captures perspectives and lessons from The Cell Summit ’26 and extends the conversation beyond the meeting itself. The post Designing the Ecosystem f…
Industry
GEN
A study in human breast organoids has found that exposure to some common endocrine-disrupting chemicals may lead to molecular changes in breast tissue that could influence susceptibility to breast cancer later in life. The post Exposure to Common Endocrine-Disrupting Chemicals Ma…
Industry P Pharmaceutical Commerce
Epic's Prescription Marketplace, due summer 2027, will show pharmacy cash prices next to insured costs before a prescription is sent.
Industry B BioPharm International
When large pharmaceutical companies deprioritize drug candidates, smaller developers may license or acquire them, but due diligence, deal structure, and trial planning determine whether a program can move forward.
Industry A Applied Clinical Trials
In this Q&A, Saamir Pasha and Carole Berini, PhD, of Ontada discuss what it takes to harmonize fragmented oncology data into reliable real-world evidence, how lab markers can proxy for missing functional status data, and where the biggest remaining barriers to consistent RWE…